Nocutil Melt (Desmopressin)

Desmopressin selectively stimulates vasopressin V2 receptors on kidney collecting‑duct cells and on endothelial cells. In the kidney this raises cAMP, causing aquaporin‑2 channels to move to the cell surface and reabsorb water. In endothelial cells it triggers release of factor VIII and von Willebrand factor, supporting haemostasis.

The appropriate dose of Nocutil Melt is set by the prescribing clinician based on the specific indication, patient age, weight, renal function and response to therapy. Dosage adjustments may be required after monitoring serum sodium and fluid balance, and the prescriber will provide individualized instructions.

Safety data for desmopressin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should weigh potential benefits against risks and discuss use with a qualified obstetrician before prescribing to pregnant or nursing women.

To order Nocutil Melt, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nocutil Melt is a sublingual melt, offering rapid absorption and ease of administration compared with nasal sprays or oral tablets. Efficacy is comparable to other desmopressin products, while the melt format may be preferred for patients who have difficulty with nasal administration or who need a discreet oral option.

Nocutil Melt should be stored at room temperature, below 25 °C, in its original blister pack. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

The melt is placed under the tongue and allowed to dissolve completely without chewing or drinking water. Administration should be performed on an empty stomach, typically at least 30 minutes before or after meals, to ensure consistent absorption.

The most serious risks include severe hyponatremia, which can cause seizures, coma or cerebral edema, and water intoxication leading to brain swelling. Patients should also be alert for signs of thromboembolic events such as unexplained leg pain or swelling, and for any allergic reactions such as rash, swelling or difficulty breathing.

Nocutil Melt should be avoided in individuals with known hypersensitivity to desmopressin, uncontrolled hyponatremia, severe renal impairment, or in patients who are already receiving other antidiuretic hormones. Caution is also advised for patients with a history of thromboembolic disease or uncontrolled hypertension.